For a leukemia that keeps returning, Abbvie drug may offer chance at deep remission

Plus: A bispecific's early promising data in triple negative breast cancer

December 13, 2024 Check out STAT+

Sponsored By

Courtesy STAT+ | For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to kick." By Angus Chen STAT+ | Pfizer's blockbuster Ibrance slows tumor progression in another type of breast cancer New efficacy data from Pfizer could help broaden use of Ibrance, and cushion losses of market share to Kisqali, a similar drug from Novartis. By Matthew Herper STAT+ | With promising early data in triple negative breast cancer, a new bispecific heats up Researchers working with BioNTech found a bispecific was effective in treating triple negative breast cancer patients in small trial. By Angus Chen Wikimedia Commons STAT+ | Stem cell transplant not needed for most mantle cell lymphoma patients, study suggests The "sledgehammer-like treatment" of stem cell transplants had no benefit for most mantle cell lymphoma patients, according to a study reported at ASH. By Angus Chen When AI becomes a tool to fight insurance denials You're reading the web edition of STAT's Health Tech newsletter, our guide to how technology is transforming the life sciences. By Mario Aguilar

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser